clinical trial · NCT04901195
A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
UCB Biopharma SRL·phase3·active not recruiting·n = 658
Hidradenitis SuppurativaBimekizumab
brief summary
The purpose of the study is to evaluate the safety of long-term therapy of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
started
May 27, 2021
primary completion
Jul 28, 2026
completion
Jul 28, 2026
last updated
May 6, 2026
official title
A Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol